Benzinga | Jun 11, 2021 08:55AM EDT

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Lowers Price Target to $205

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Equal-Weight and lowers the price target from $254 to $205.